ERBB2 and breast carcinoma: In a retrospective analysis of HER2-positive metastatic or recurrent breast cancer with brain metastasis, patients treated with both trastuzumab and lapatinib after developing metastasis had a significantly longer survival than patients treated with trastuzumab alone, lapatinib alone, or no HER2-targeting agent (p < 0.001) [96].